CD19 and neoplasm: Anti-CAIX CAR T cells that secrete PD-L1 antibodies in murine renal cell carcinoma [96] or anti-CD19 CAR T cells secreting PD-1-blocking single-chain variable fragments (scFv) [97] showed improved anti-tumor activity of CAR T cells that was superior to conventional CAR-T cells in vivo.